

CHANGE OF AUDITOR

Melbourne, Australia, 9 February 2021: BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or the **Company**) announces that Grant Thornton Audit Pty Ltd (Grant Thornton) have been appointed the Company's auditors with effect from 9 February 2021. The appointment has been formally approved by the Australian Securities & Investment Commission (ASIC) and, as part of the transition process, a letter of resignation has been received from Ernst & Young.

The Board undertook a tender and consultation process following the merger with Sienna Cancer Diagnostics Ltd. Grant Thornton were selected based on their reputation and experience, particularly their experience in the Biotechnology sector.

In accordance with section 327C of the Corporations Act 2001, a resolution will be tabled at the Company's 2021 Annual General Meeting to ratify the appointment of Grant Thornton as the auditor of BARD1.

The Board would like to take this opportunity to thank Ernst & Young for their professional service.

Authorised by the Company Secretary, Tony Di Pietro.

- ENDS -

COMPANY CONTACTS

Dr Leearne Hinch

CEO

E leearne@bard1.com

M +61 400 414 416

Dr Geoff Cumming

Non-executive Chairman

E geoff.cumming@bard1.com

M +61 417 203 021

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) (**BARD1** or the **Company**) is a leading Australian diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising best-in-class diagnostic solutions for healthcare professionals and patients. The cancer diagnostics portfolio includes the commercialised hTERT test used as an adjunct to urine cytology testing, and diagnostic tests in development for ovarian, breast, lung, prostate and pancreatic cancers. For more information on BARD1, see www.bard1.com.

FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.